Healthcare / BiotechnologyNasdaqCM
$18.82
-0.36 (-1.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-117.1M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-74.7%
↓Gross Margin
N/A
•Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-227.3M · FCF $-196.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-227.3M | $-227.3M | $-118.9M | $-36.0M | $-50.0M | $-4.5M | — |
| EBITDA | $-219.8M | $-219.8M | $-119.6M | $-43.6M | $-64.9M | — | — |
| EPS | -3.53 | -3.53 | -1.89 | -0.73 | -1.28 | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.25 | 0.25 | 0.01 | 0.01 | 0.01 | — | — |
| Current Ratio | 8.60 | 8.60 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-196.0M | $-196.0M | $-117.1M | $-43.1M | $-55.9M | — | — |
| Returns | |||||||
| ROE | -74.7% | -74.7% | -26.6% | -7.3% | -102.2% | 39.0% | — |
| Valuation | |||||||
| P/B | 3.98 | 3.98 | 7.52 | 5.42 | 9.98 | — | — |
| Growth & Yield | |||||||
| EPS Growth | -86.8% | -86.8% | -158.9% | 43.1% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.89 → -3.53
Residual
-51.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.